🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

107 results for “Eli Lilly Co.” Clear

  1. RAMUCIRUMAB, ERLOTINIB

    Eli Lilly Co.

    Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  2. Remternetug, Placebo to match LY

    Eli Lilly Co.

    Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  3. Retatrutide, Tirzepatide, Retatrutide, Tirzepatide, Tirzepatide, Tirzepatide, Retatrutide, Retatrutide, Retatrutide, Tirzepatide, Tirzepatide

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial

  4. SELPERCATINIB, CARBOPLATIN , SELPERCATINIB, PEMBROLIZUMAB, CISPLATIN , PEMETREXED

    Eli Lilly Co.

    Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  5. TAMOXIFEN , EXEMESTANE , ANASTROZOLE , LETROZOLE , Verzenios 50 mg film-coated tablets

    Eli Lilly Co.

    Breast Cancer

    phase 3 small molecule active

    1 trial

  6. TIRZEPATIDE, TIRZEPATIDE, Retatrutide, Retatrutide, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, Retatrutide, Retatrutide, TIRZEPATIDE, Placebo to match LY, Retatrutide, Placebo to match LY

    Eli Lilly Co.

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 3 small molecule active

    1 trial

  7. TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, Placebo to match LY3298176, TIRZEPATIDE, TIRZEPATIDE

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  8. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Mirikizumab, Mirikizumab, to match Tirzepatide, Tirzepatide, Mirikizumab, Tirzepatide

    Eli Lilly Co.

    Obesity or Overweight, Crohn’s Disease

    phase 3 small molecule active

    1 trial

  9. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Placebo to match LY3298176 injection

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial

  10. Tocilizumab, Placebo to match 2 mg/mL oral suspension, BARICITINIB, Baricitinib, Placebo to match 4 mg tablet, TOCILIZUMAB , Placebo to match 2 mg tablet, JAK1/JAK2 inhibitor, Placebo to match 1 mg tablet, BARICITINIB

    Eli Lilly Co.

    Systemic Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  11. 0.9% sodium chloride, GADOTERIC ACID

    Eli Lilly Co.

    Relapsing Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  12. Abemaciclib, Abemaciclib, Verzenios 50 mg film-coated tablets, TEMOZOLOMIDE

    Eli Lilly Co.

    Glioma

    phase 2 small molecule active

    1 trial

  13. Abemaciclib, TEMOZOLOMIDE , Verzenios 50 mg film-coated tablets, IRINOTECAN

    Eli Lilly Co.

    Relapsed/Refractory Solid Tumors

    phase 2 small molecule active

    1 trial

  14. Brenipatide, Brenipatide, Brenipatide, Brenipatide, Placebo to match LY

    Eli Lilly Co.

    Asthma

    phase 2 small molecule active

    1 trial

  15. Eltrekibart, 0.9% sodium chloride

    Eli Lilly Co.

    Moderate to Severe Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  16. Eltrekibart, 0.9% sodium chloride, Mirikizumab, Mirikizumab, Placebo for LY3074828 SC Injection, 1mL Prefilled Syringe

    Eli Lilly Co.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  17. FLORBETAPIR, Placebo to match LY, Flortaucipir, Donanemab

    Eli Lilly Co.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  18. Flortaucipir, Placebo to match LY3372689

    Eli Lilly Co.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  19. IOHEXOL , Placebo to match LY3437943, Retatrutide

    Eli Lilly Co.

    Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  20. KEYTRUDA 25 mg/mL concentrate for solution for infusion, CETUXIMAB, olomorasib

    Eli Lilly Co.

    KRAS G12C-Mutant Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  21. LY2875358, ERLOTINIB

    Eli Lilly Co.

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  22. ONDANSETRON , APREPITANT , PALONOSETRON, COMBINATIONS, PALONOSETRON , Lagipra, GRANISETRON , DEXAMETHASONE , 0.9% sodium chloride

    Eli Lilly Co.

    Nausea, Drug-Related Side Effects and Adverse Reactions, Vomiting, Neoplasms

    phase 2 small molecule active

    1 trial

  23. Pirtobrutinib, Placebo tablets

    Eli Lilly Co.

    Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  24. Placebo to match LY, Mirikizumab, Placebo to Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources